Protocol summary

Study aim
Comparing the effects and side effects of two drugs, Dysport and Masport
Design
A clinical trial with 2 random groups, Masport and Dysport, double-blind, randomized, phase 2 on 160 patients.
Settings and conduct
This study will be conducted in the oculoplastic clinic of Farabi Hospital in Tehran, Iran. The study will be conducted in a double-blind manner, and none of the doctors and patients will know the type of injected drug. Before and after the injection, the questionnaire is completed by the patients and the relevant doctor. Before and after the injection, the faces of the patients are photographed while laughing, frowning, and indifference. The patients are followed up at intervals of 2 weeks, 2 months, and 4 months after the injection.
Participants/Inclusion and exclusion criteria
1-Physical and mental health of the participants 2- Decision-making power and completely voluntary participation in the study 3- Allowed age range 27-57 4- Confirmation of the need for injection by the doctor and the candidate for Botox injection 5-Candidates for oculoplasties
Intervention groups
Patients in two intervention groups are included in the study, 80 people will be injected with masport drug and 80 people will be injected with dysport drug. The study was double-blind and none of the patients and related doctors knew about the type of medicine.
Main outcome variables
1- Investigating the effect of two drugs in the same doses in removing and reducing the depth of wrinkles in patients 2- Examining the short-acting and long-acting side effects of both drugs, including inflammation, redness, and drooping of the eyelids. 3- Checking the shelf life of two drugs 4- Checking the need for re-injection and restoration of two drugs at intervals of 2 weeks, 2 months and 4 months

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20230727058942N1
Registration date: 2023-12-18, 1402/09/27
Registration timing: registered_while_recruiting

Last update: 2023-12-18, 1402/09/27
Update count: 0
Registration date
2023-12-18, 1402/09/27
Registrant information
Name
Ghazal Ghochani
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 31 3669 5248
Email address
gghochani@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2023-08-27, 1402/06/05
Expected recruitment end date
2024-02-24, 1402/12/05
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparison of the effects and side effects of Dysport and Masport in patients referred to the ultra-specialized oculoplasty clinic of Farabi Hospital in 1402
Public title
comparison between masport and dysport in facial botox
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Physical and mental health The ability to make decisions regarding voluntary participation in the study Permissible age range in study (27-54 years old) Botox injection candidate in the studied areas
Exclusion criteria:
History of heavy surgeries and any type of fracture in any part of the face History of stroke and facial paralysis
Age
From 27 years old to 57 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
  • Outcome assessor
  • Data analyser
Sample size
Target sample size: 160
Randomization (investigator's opinion)
Randomized
Randomization description
Randomization is performed using a stratified permuted block randomization method with random block lengths (2, 4, 6). After screening, patients will be randomly assigned to groups A and B in a 1:1 ratio to receive Dysport or Masport injections. Stratification variables, including age and gender, will be determined as follows: ARMS (RATIOS: 1:1): * A * B STRATIFY: Yes TOTAL STRATA: 4 STRATIFICATION VARIABLES: 1) Sex: * male * female 2) age: * <40 * >40 For this purpose, a randomization program was written in R software with the help of the center's biostatistician, and the randomization output was produced as an Excel file. Patients, researchers, and site personnel (except pharmacists) are blinded to the type of injectable drug and will remain so until the end of the follow-up period and analysis of the study data.
Blinding (investigator's opinion)
Double blinded
Blinding description
In this study, which is a kind of double-blind study, all participating patients and doctors involved, including the relevant professor who is responsible for the injection and the relevant resident who is responsible for coordinating and writing articles and theses, as well as the nurse related to The design is all kept blind during the design and it is an injectable drug type (Mesport or Dysport brand) do not know. Injection vials are prepared in completely identical and similar syringes by the relevant person and brought to the hospital.
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Tehran University of Medical Sciences
Street address
Farabi Ophthalmology Hospital, Qazvin Square, Tehran
City
tehran
Province
Tehran
Postal code
1336616351
Approval date
2023-07-22, 1402/04/31
Ethics committee reference number
IR.TUMS.FARABIH.REC.1402.015

Health conditions studied

1

Description of health condition studied
Investigating the therapeutic effects of two drugs, MASPORT and DYSPORT, on wrinkles around the eyes. forehead
ICD-10 code
H00-H06
ICD-10 code description
بررسی اختلالات کاسه چشم و پلک ها

Primary outcomes

1

Description
1- To investigate the effect of two drugs in the same doses in removing and reducing the depth of wrinkles in patients.
Timepoint
At the beginning of the study, the day of injection, 14 days later, 2 months later and 4 months after injection
Method of measurement
A questionnaire prepared and completed by the doctor and the patient and photos taken of the target areas before and after the injection, which examines the function of the frown muscles and forehead muscles.

2

Description
2- Examining the short-acting and long-acting side effects of both drugs, including inflammation, redness, and drooping of the eyelids.
Timepoint
At the beginning of the study, the day of injection, 14 days later, 2 months later and 4 months after injection
Method of measurement
A questionnaire prepared and completed by the doctor and the patient and photos taken of the target areas before and after the injection, which examines the function of the frown muscles and forehead muscles.

3

Description
3- Checking the shelf life of two drugs
Timepoint
At the beginning of the study, the day of injection, 14 days later, 2 months later and 4 months after injection
Method of measurement
A questionnaire prepared and completed by the doctor and the patient and photos taken of the target areas before and after the injection, which examines the function of the frown muscles and forehead muscles.

4

Description
4- Checking the need for re-injection and restoration of two drugs at intervals of 2 weeks, 2 months and 4 months.
Timepoint
At the beginning of the study, the day of injection, 14 days later, 2 months later and 4 months after injection
Method of measurement
A questionnaire prepared and completed by the doctor and the patient and photos taken of the target areas before and after the injection, which examines the function of the frown muscles and forehead muscles.

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: Intervention group 1: under MASPORT injection. Each person is injected with 110 units of medicine that contains the chemical composition of botulinum toxin and is manufactured by Masoun Daru pharmaceutical company with the permission of the Ministry of Health in Iran. 500 vials of this medicine are diluted with 2.6 cc of distilled water and placed in an anonymous and unmarked vial for the validity of randomization, and in each person, 50 units of the forehead area, 30 units of the frown line, and 30 units of the wrinkles around the eyes are injected with a syringe. In this study, 1 injection was performed.
Category
Treatment - Drugs

2

Description
Control group: intervention group 2: they are subjected to DYSPORT injection. Each person is injected with 110 units of medicine that contains the chemical composition of botulinum toxin and is available in the country under the brand name DYSPORT with the official license of the Ministry of Health as an import made in Italy or France. 500 vials of this medicine are diluted with 2.6 cc of distilled water and placed in an anonymous and unspecified vial for the validity of randomization, and 50 units of the forehead area, 30 units of the frown line, and 30 units of the wrinkles around the eyes are injected with an insulin syringe. In this study, 1 injection was performed
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Farabi eye hospital
Full name of responsible person
Ghazal ghochani
Street address
Farabi Ophthalmology Hospital, Qazvin Square, Tehran
City
TEHRAN
Province
Tehran
Postal code
136616351
Phone
+98 21 5540 0003
Email
Gghochani@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Vice President of Research and Technology
Street address
Farabi Ophthalmology Hospital, Qazvin Square, Tehran
City
tehran
Province
Tehran
Postal code
1336616351
Phone
+98 912 112 0781
Email
Gghochani@gmail.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
No
Title of funding source
Masoun Daro Company
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Other

Person responsible for general inquiries

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Ghazal ghochani
Position
resident
Latest degree
Medical doctor
Other areas of specialty/work
Ophthalmology
Street address
Farabi Ophthalmology Hospital, Qazvin Square, Tehran
City
tehran
Province
Tehran
Postal code
136616351
Phone
+98 21 5540 0003
Email
Gghochani@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Ghazal Ghochani
Position
resident
Latest degree
Medical doctor
Other areas of specialty/work
Ophthalmology
Street address
Farabi Ophthalmology Hospital, Qazvin Square, Tehran
City
tehran
Province
Tehran
Postal code
136616351
Phone
+98 21 5540 0003
Email
Gghochani@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Ghazal Ghochani
Position
resident
Latest degree
Medical doctor
Other areas of specialty/work
Ophthalmology
Street address
Farabi Ophthalmology Hospital, Qazvin Square, Tehran
City
tehran
Province
Tehran
Postal code
1336616351
Phone
+98 21 5540 0003
Email
Gghochani@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...